Agios Pharmaceuticals Inc (AGIO):企業の財務・戦略的SWOT分析

◆英語タイトル:Agios Pharmaceuticals Inc (AGIO) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH135515FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥68,400見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥102,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company that focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company’s products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 enzyme used for the treatment of patients with R/R acute myeloid leukemia (AML); and TIBSOVO (ivosidenib), a prescription medicine used to treat adults with AML. Its pipeline products include AG-881, a pan-IDH mutant inhibitor intended for the treatment of hematologic malignancies and solid tumors; AG-270, an inhibitor of methionine adenosyltransferase 2a; and Mitapivat, a potent activator intended for the treatment of patients with pyruvate kinase deficiency. Agios is headquartered in Cambridge, Massachusetts, the US.

Agios Pharmaceuticals Inc Key Recent Developments

Mar 18,2021: Agios sponsors program promoting health literacy for patients with sickle cell disease
Feb 26,2021: Agios recognizes 14th annual Rare Disease Day and raises awareness of unmet needs in rare hemolytic anemias
Feb 25,2021: Agios reports fourth quarter and full year 2020 financial results
Feb 23,2021: Agios to Present at March Investor Conferences
Jan 11,2021: Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021

This comprehensive SWOT profile of Agios Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Agios Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Agios Pharmaceuticals Inc – Key Information
Agios Pharmaceuticals Inc – Overview
Agios Pharmaceuticals Inc – Key Employees
Agios Pharmaceuticals Inc – Key Employee Biographies
Agios Pharmaceuticals Inc – Key Operational Heads
Agios Pharmaceuticals Inc – Major Products and Services
Agios Pharmaceuticals Inc – History
Agios Pharmaceuticals Inc – Company Statement
Agios Pharmaceuticals Inc – Locations And Subsidiaries
Agios Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Agios Pharmaceuticals Inc – Business Description
Agios Pharmaceuticals Inc – Corporate Strategy
Agios Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Agios Pharmaceuticals Inc – Strengths
Agios Pharmaceuticals Inc – Weaknesses
Agios Pharmaceuticals Inc – Opportunities
Agios Pharmaceuticals Inc – Threats
Agios Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Agios Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Agios Pharmaceuticals Inc, Key Information
Agios Pharmaceuticals Inc, Key Ratios
Agios Pharmaceuticals Inc, Share Data
Agios Pharmaceuticals Inc, Major Products and Services
Agios Pharmaceuticals Inc, History
Agios Pharmaceuticals Inc, Key Employees
Agios Pharmaceuticals Inc, Key Employee Biographies
Agios Pharmaceuticals Inc, Key Operational Heads
Agios Pharmaceuticals Inc, Other Locations
Agios Pharmaceuticals Inc, Subsidiaries
Agios Pharmaceuticals Inc, Key Competitors
Agios Pharmaceuticals Inc, SWOT Analysis
Agios Pharmaceuticals Inc, Ratios based on current share price
Agios Pharmaceuticals Inc, Annual Ratios
Agios Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Agios Pharmaceuticals Inc (AGIO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ABC Supply Co. Inc.:企業のM&A・事業提携・投資動向
    ABC Supply Co. Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ABC Supply Co. Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • MDNA Life Sciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary MDNA Life Sciences Inc (MDNA) is a molecular diagnostics company that develops molecular tests based on the mitochondrial genome. The company’s prostate core mitomic test is based on the science of mitochondrial DNA, a tissue-based prostate cancer diagnostics for prostate and other cancers. …
  • Formula Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Formula Pharmaceuticals Inc (Formula Pharmaceuticals) is a biopharmaceutical company that develops chimeric antigen receptor immunotherapy for oncology and autoimmune diseases. The company provides its pipeline products such as CIK-CAR.CD19, used as B-lymphocyte surface antigen; CIK-CAR.CD33 …
  • Bounty Developments Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Bounty Developments Ltd (Bounty Developments) is an oil and gas company that offers exploration and production of crude oil and natural gas. The company owns and operates vertical and horizontal oil and gas wells. It acquires and develops PNG, oilsands and light oil resource projects. Bounty …
  • The Mauritius Commercial Bank Limited:企業の戦略・SWOT・財務分析
    The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report Summary The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • OSE Immunotherapeutics (OSE):企業の財務・戦略的SWOT分析
    Summary OSE Immunotherapeutics (OSE), formerly OSE Pharma SA is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and …
  • Amer Sports Corporation:企業の戦略・SWOT・財務情報
    Amer Sports Corporation - Strategy, SWOT and Corporate Finance Report Summary Amer Sports Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • OraSure Technologies Inc (OSUR):企業の財務・戦略的SWOT分析
    OraSure Technologies Inc (OSUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Zagro Asia Ltd:企業の戦略的SWOT分析
    Zagro Asia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • The Cooper Companies, Inc.:企業の戦略・SWOT・財務情報
    The Cooper Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Cooper Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • FibroStatin SL:製薬・医療:M&Aディール及び事業提携情報
    Summary FibroStatin SL (FibroStatin) is a drug development company that focuses on the development of treatment candidates for drug resistant lung cancer and idiopathic pulmonary fibrosis. The company’s pipeline products include T12/FST12 for NSCLC, GPBP-Mab/FSM26 for idiopathic pulmonary fibrosis a …
  • Wells Fargo Clearing Services LLC:企業の戦略・SWOT・財務分析
    Wells Fargo Clearing Services LLC - Strategy, SWOT and Corporate Finance Report Summary Wells Fargo Clearing Services LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • OncoSil Medical Ltd (OSL):医療機器:M&Aディール及び事業提携情報
    Summary OncoSil Medical Ltd (OncoSil), formerly Neuro Discovery Ltd, is a medical device company that develops and commercializes products for the treatment of pancreatic and liver cancer. The company’s lead product includes oncosil, a brachytherapy device that emits beta radiation and is implanted …
  • Abreos Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Abreos Biosciences Inc (Abreos Biosciences) is a biotechnology company that develops laboratory-based and point-of-care (POC) tests for precision dosing of biologic drugs. The company’s technology platform veritope, allow monitoring of monoclonal antibody drug levels in blood (novel or biosi …
  • Abano Healthcare Group Ltd (ABA)-製薬・医療分野:企業M&A・提携分析
    Summary Abano Healthcare Group Ltd (Abano Healthcare), formerly ElderCare New Zealand Ltd is a healthcare service provider that offers Dental, Audiology, Radiology and medical services. The company also operates business in community pathology and radiology sector. It operates businesses in sectors …
  • Nippon Shokubai Co Ltd (4114):企業の財務・戦略的SWOT分析
    Nippon Shokubai Co Ltd (4114) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • BE Semiconductor Industries N.V. (BESI):企業の財務・戦略的SWOT分析
    BE Semiconductor Industries N.V. (BESI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Biotec Pharmacon ASA (BIOTEC):企業の財務・戦略的SWOT分析
    Summary Biotec Pharmacon ASA (Biotec Pharmacon) is a biopharmaceutical company that develops, manufactures and markets immune modulating compounds and cold adapted enzymes. The company provides products which are used in the areas of human medicine such as immunotherapy of cancer, general infection …
  • Coloplast AS (COLO B):企業の財務・戦略的SWOT分析
    Coloplast AS (COLO B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • J.Crew Group, Inc.:企業の戦略・SWOT・財務分析
    J.Crew Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary J.Crew Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆